medical firms that should be high on the target acquisition list for tax inversion deals. Ireland-based Perrigo (NYSE: PRGO ), Switzerland-based Actelion and U.K.-based Smith & Nephew Plc (NYSE: SNN ) ( OTCQB:SNNUF ) are all attractive targets
like to own stocks that have FCC investigations. Now that has passed. It seems like an inexpensive stock." Perrigo (NYSE: PRGO ): "I believe the rumors that Perrigo might end up getting a bid, and I like the earnings profile from Perrigo." Rite Aid
the U.S. under the brand name Effexor XR. Sun is also recalling 200 vials of the chemo drug gemcitabine in the U.S. due to a lack of assurance of sterility. Related tickers: ( TEVA ) ( RDY ) ( MYL ) ( MNK ) ( PRGO ) Post your comment!
it makes it harder for Allergan to buy Shire and get a tax inversion. Perrigo is undervalued My estimate for Perrigo Company 's ( PRGO ) earnings for the next 12 months is around $8 (see this article for details ). That means Perrigo trades
By Uncommon Profit Investor : Introduction Perrigo Company PLC ( PRGO ) has a market cap of $18.6 billion with revenue in the latest quarter of $1 billion. Perrigo make store-brand medications
pharma. His picks are AGN, ESRX, ISRG, REGN, RHHBY ; also mentioned are BIIB, GILD, PCYC, MDVN, ALPMY, ABBV, JAZZ, PRGO , ACT, JNJ, BMY, MRK, A . Pg 30: Electronic investor analyses various portfolios and concludes that a 60-40 portfolio
Perrigo benefits from weak economic conditions, competitor recalls, and opportunistic acquisitions.
cyclical/2.322% in each CHD, FHCO, JJSF and VLGEA/consumer defensive/2.55% in each ATRI, GILD, IDXX, MLAB, NVO and PRGO /healthcare/2.147% in each ATNI/communication services/3.83%; and lastly CERN, CNQR, TYL/technology/5.51
basis. They're not cheap but definitely worth a buy when they rarely tank. Here they are: DORM, EXPO, GILD, IT JBHT, PRGO TSCO, and WAB. Keep an eye on them; write those broker's checks when they correct and enjoy huge low volatility, low risk
Perrigo PRGO announced that it will acquire Elan ELN in an $8.6 billion stock and cash deal, or $6.7 billion excluding Elan’s nearly